MedTrace Logo

Sirtuin Activators and Weight Loss

NCT07802548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-09-03

No results posted yet for this study

Summary

Obesity is a chronic, multifactorial disease associated with a high burden of metabolic, cardiovascular, and psychosocial complications. Despite extensive research, the long-term effectiveness of lifestyle-based weight-management strategies remains limited, and there is a growing interest in molecular pathways that may enhance metabolic flexibility and improve treatment outcomes. Among these pathways, the sirtuin (SIRT) family-particularly SIRT1 and SIRT3-has emerged as a promising target due to its involvement in mitochondrial biogenesis, energy expenditure, oxidative metabolism, and the regulation of insulin sensitivity. Bioactive compounds that activate sirtuins, including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), resveratrol, and selected polyphenols, have shown metabolic benefits in preclinical models; however, high-quality human trials remain scarce and inconsistent.

This project aims to investigate the efficacy of a standardized sirtuin-activator supplement on body-weight reduction, metabolic health, and energy-balance regulation in adults with overweight and obesity. The trial will be a randomized, double-blind, placebo-controlled intervention lasting 24 days. Participants will be assigned to either the sirtuin-activator group or placebo, with both groups receiving standardized dietary plan to ensure consistent caloric intake. The primary outcome will be absolute and relative weight loss, while secondary outcomes will include changes in waist circumference, body-composition parameters, resting metabolic rate, glycemic markers, lipid profiles and physical functioning.

A key novelty of this project lies in testing a multi-ingredient formulation designed to synergistically enhance sirtuin signaling, addressing limitations observed in studies using single-compound approaches. By integrating nutritional guidance, rigorous clinical monitoring, and advanced biomarker profiling, this research aims to generate high-quality evidence on whether sirtuin activators can meaningfully augment weight-loss interventions in humans.

Conditions

  • Obesity & Overweight

Interventions

DIETARY_SUPPLEMENT

SIRTUIN activators + weight loss diet

Sirtuin activators: EGCG, resveratrol, quercetin, niacin, curcuminoids with weight loss diet

DIETARY_SUPPLEMENT

Placebo supplementation + weight loss diet

Identical placebo with weight loss diet

Sponsors & Collaborators

  • Poznan University of Life Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-19
Primary Completion
2026-07-30
Completion
2026-07-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07802548 on ClinicalTrials.gov